anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a preparation technology and a production method for an integrated new formulation of a licorice and dried ginger decoction, wherein the raw materials of active ingredients comprise: 12 parts by weight of honey-fried licorice root and 6 parts by weight of dried ginger. The production process of the integrated new formulation comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of licorice and dried ginger decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of licorice and dried ginger decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of licorice and dried ginger decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
All of the patients will receive apatinib at oral dose of 250 mg twice daily (500 mg/day) at least 30 days.One treatment cycle is defined as 4 weeks.18F-ALF-NOTA-PRGD2 PET/CT scan will be performed berore and after one cycle of therapy. Treatment interruptions or dose reductions to 250 mg/day will be allowed for the management of adverse events. The maximum allowable period of treatment interruption is 1 week during each treatment cycle, and the dose should be re-escalated to 500 mg/day after adverse events mitigation. Treatment will not stop until disease progression, intolerable toxicity, or patients' request for withdrawal from the study.
Pemetrexed and cisplatin will be administered intravenously for a total of 4 to 6 cycles. Participants will receive 4 cycles, but can receive up to 6 cycles based on clinician discretion. Substitution with carboplatin allowed for pre-existing impairment of hearing, renal function, or neuropathy.
Participants randomized to this arm will be connected with Scene Health by a study staff member (not the PI or Co-I's). After submitting and receiving approval of a test video submission, the participants' hydroxyurea dosing schedule will be entered into the VDOT app by the research staff and will be updated by these staff after their routine hematology visits and/or hospitalizations. Participants will receive VDOT for 180 days, beginning the day after randomization. After that time, they will start a 180-day ongoing monitoring period, during which VDOT participants will receive monthly telephone calls and intermittent text messages from Scene Health staff to encourage ongoing adherence. The Scene Health staff will access the electronic adherence platform and use this data to inform their communications during the ongoing monitoring period. Participants in both arms will be offered a smartphone with a data plan at enrollment to ensure equal opportunity for participation.
We investigated the relationship between neutrophil apoptosis and endoplasmic reticulum stress (ERS) in sepsis and its mechanism. A prospective cohort study was conducted by recruiting a total of 58 patients with sepsis. Peripheral blood samples were collected on 1, 3, 5 and 7 days after admission to the ICU. The expressions of endoplasmic reticulum specific glucose regulatory protein 78 (GRP78), C/EBP homologous protein (CHOP), apoptosis signal-regulating kinase 1 (ASK1), Bcl-2-like 11 (BIM), death receptor 5 (DR5), c-Jun N-terminal kinases (JNK) and p38 were detected by Western blot and PCR. The subcellular location of CHOP and GRP78 was observed by immunofluorescence analysis. Spearman correlation was used to analyze the correlation between the expression of chop protein and the apoptosis rate of peripheral blood neutrophils. Healthy volunteers in the same period were selected as the healthy control group. The expression of GRP78 protein was significantly elevated on the first day of ICU admission and showed a decreasing trend on the third, fifth and seventh day, but was significantly higher than the corresponding healthy control group. The expression of CHOP protein reached the highest level on the third day. The expression of chop protein in each group was significantly higher than that in the corresponding healthy control group. Immunofluorescence staining clearly showed that the CHOP protein accumulated in the nucleus, with an elevation in the intensity of GRP78. The neutrophil apoptosis rate of sepsis patients on the 1st, 3rd, 5th and 7th day of ICU stay was significantly higher than that of the healthy control group, with the highest apoptosis rate on the 3rd day, and then decreased gradually. CHOP protein expression level was significantly positively correlated with neutrophil apoptosis rate in sepsis patients. Endoplasmic reticulum stress occurs in neutrophils during the development of sepsis. GRP78 protein and CHOP protein may be involved in the pathological process of neutrophil apoptosis in sepsis.
FIELD: medicine, pediatrics, pharmacy. SUBSTANCE: invention relates to sedative medicinal composition with mild effect. Composition with sedative activity comprises valerian biologically active substances, sodium bromide, magnesium sulfate, citral preparation and glucose. As biologically active substances the composition contains effective amount of valepotriates as components of valerian dry extract and citral as oil and it comprises optionally solvent (up to volume 100 ml) and components are taken in the definite ratio. Composition can be made as dry mixture or an aqueous or alcoholic 20% solution. Invention provides the required quality of dry mixture corresponding to requirements of Pharmacopoeia and useful life 1 year, not less. EFFECT: enhanced and valuable properties of composition. 4 cl, 2 tbl
Ischemia/reperfusion (I/R) is an important inducer of acute kidney injury (AKI), and triggers the generation of reactive oxygen species (ROS) and the expression of matrix metalloproteinase 2 (MMP2), exacerbating kidney damage. Given the immense potential of vitamin E (VitE) as a natural fat-soluble antioxidant in kidney protection, we designed the nanoparticles (NPs) that could dual respond to ROS and MMP2, aiming to accurately deliver VitE to renal injury cells. The NPs utilized Gel-SH as a sensitive receptor for MMP2 and diselenide as a sensitive receptor for ROS, while PEG2k modification enhanced biocompatibility and prevented phagocytosis mediated by the mononuclear phagocyte system. The amphiphilic Gel-SH and diselenide encapsulate the liposoluble VitE and self-assemble into the NPs with a hydrodynamic size of 69.92 nm. Both in vivo and in vitro experiments based on these NPs show good biocompatibility and the ability of target renal injury cells. In vivo kidney I/R injury models and in vitro cell hypoxia/reoxygenation models, the NPs have demonstrated effects in reducing oxidative stress and alleviating AKI. Notably, VitE can preferentially react with peroxyl radical (LOO•) than polyunsaturated fatty acid (PUFA), inhibiting the formation of carbon centered radical (L•), thereby blocking the chain reaction between PUFA and LOO• in ferroptosis. The NPs also inhibit the transition from AKI to chronic kidney disease, with few side effects. Thus, the NPs with dual-responsiveness to MMP2 and ROS for targeted delivery of VitE to renal injury cells exhibit remarkable effects in inhibiting ROS and the chain reactions of ferroptosis, making it a promising therapeutic agent against AKI caused by I/R.
PURPOSE: A pharmaceutical composition for preventing and treating chronic obstructive pulmonary diseases is provided to offer medicine or health food for preventing and treating chronic obstructive pulmonary diseases by containing the extract of Phyllostachys nigra Munro var. henosis Stapf for reducing histiocytes in bronchoalveloar lavage fluid and neutophils as an active ingredient. CONSTITUTION: A pharmaceutical composition for preventing and treating chronic obstructive pulmonary diseases contains the extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient. The chronic pulmonary diseases are chronic bronchitis and pulmonary emphysema. A pharmaceutical composition for health food to prevent and treat chronic obstructive pulmonary diseases contains the extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient. A pharmaceutical composition for preventing and treating pulmonary diseases contains the extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient. [Reference numerals] (AA) Total inflammatory cell in pulmonary washing solution (×10^6); (BB) Bambusae caulis in Taenian
PURPOSE:To obtain the titled soft capsule containing Lactobacillus bifidus in a state survivable stably for a long period without emitting ill odor, by adding a protective agent to the powder of the bifidus bacteria, suspending in a hardened oil having narrow melting point range to obtain the core liquid for capsule, and encapsulating the core liquid with a gelatin skin. CONSTITUTION:Bifidus bacteria are added with a protective agent (preferably dried starch), and suspended in a hardened oil having a melting point of 30-45 deg.C and melting point range of <=3 deg.C (e.g. coconut oil, palm kernel oil, etc.), and the obtained core oil is encapsulated with a gelatin skin to obtain the titled soft capsule. The solid content of the gelatin solution is preferably 20-35%, and the gelatin is preferably added with pectin and sodium alginate. A soft capsule prepared by this process is free from characteristic ill odor of bifidus bacteria, has excellent palatability and has high survivability of the bifidus bacteria in the capsule. The bifidus bacteria useful as an intestine-conditioning agent reaches the intestine in living state.
<P>PROBLEM TO BE SOLVED: To provide a composition that positively promotes regenerating performances of a living organism involving healing of a damage in a skin epithelial tissue such as a wound or ulcer thereby to reduce the time till complete healing of the damage and is highly safe with significantly reduced danger of side effects.  <P>SOLUTION: A pharmaceutical composition for indirect administration comprising a component derived from Momordica grosvenori for treating a damage in a skin epithelial tissue such as a wound or ulcer and a food composition comprising a component derived from Momordica grosvenori for treating a damage in a skin epithelial tissue such as a wound or ulcer are provided. In one embodiment, the indirect administration is achieved by administering the composition to a part other than a part to be treated. In one embodiment, the component is an extract of Momordica grosvenori. The extract of Momordica grosvenori comprises typically at least one Momordica grosvenori glycoside. The Momordica grosvenori glycoside is selected from the group consisting of mogroside IV, mogroside V, cyamenoside I and 11-oxo-mogroside V.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Variation in body weight (BW) within broiler flocks is a significant challenge in poultry production. Investigating differences in gut-related parameters between low (LBW) and high BW (HBW) chicks may provide insights into the underlying causes of BW heterogeneity. 908 day-old male broiler chicks were reared until d 7 and then ranked into LBW and HBW groups. Thereafter, performance parameters were compared between BW groups periodically. On d 7, 14, and 38, visceral organ characteristics, intestinal permeability, and duodenal and ileal histomorphology were examined. Expression profiles were analyzed for 79 ileal genes related to gut barrier function, immune function, nutrient transport, gut hormones, nutrient receptors, metabolism, and oxidation using high-throughput qPCR. Student's t-tests were performed to compare measurements. Multivariate statistics, including partial least square regression (PLSR) analysis, were applied to identify combinations of key genes discriminating BW groups, offering predictive capability for phenotypic variations. The HBW group remained heavier at each timepoint, which could be explained by higher feed intake. The HBW group had shorter relative small intestine length but higher villus height and villi height/crypt depth ratios. The LBW group demonstrated increased intestinal permeability on d 38. The LBW group showed upregulation of immune response genes including TNF-α on d 7 and CYP450 on d 38, while the HBW group showed higher AHSA1 and HSPA4 expressions on d 7. The LBW group had upregulation of the metabolism genes mTOR and EIF4EBP1 on d 7 and the satiety-induced hormone cholecystokinin on d 14, while the HBW group tended to increase expression of the hunger hormone ghrelin on d 38. Genes related to gut barrier function, nutrient transport, and oxidation categories were consistently upregulated in the HBW group. PLSR models revealed 4, 12, and 11 sets of key genes highly predictive of BW phenotypes on d 7, 14, and 38, respectively. These findings suggest that growth rates are linked to the intestinal size, structure, and function of broiler chickens, offering insights into the underlying mechanisms regulating BW.
Lateral hypothalamic (LH) hypocretin/orexin neurons (HONs) control brain-wide electrical excitation. Abnormally high excitation produces epileptic seizures, which affect millions of people and need better treatments. HON population activity spikes from minute to minute, but the role of this in seizures is unknown. Here, we describe correlative and causal links between HON activity spikes and seizures. Applying temporally-targeted HON recordings and optogenetic silencing to a male mouse model of acute epilepsy, we found that pre-seizure HON activity predicts and controls the electrophysiology and behavioral pathology of subsequent seizures. No such links were detected for HON activity during seizures. Having thus defined the time window where HONs influence seizures, we targeted it with LH deep brain stimulation (DBS), which inhibited HON population activity, and produced seizure protection. Collectively, these results uncover a feature of brain activity linked to seizures, and demonstrate a proof-of-concept treatment that controls this feature and alleviates epilepsy.
A functional intimate apparel will be provided to patient to wear it 8 hours daily. Monitoring and observation will be provided during the 6-9 months wearing period.
The invention provides nucleic acid molecules, proteins, compositions and methods for treating brain cancer in a subject. In certain embodiments, the composition comprises cancer antigens hTERT, WT-1 and PSMA. In certain embodiments, the composition further comprises an adjuvant. The method comprises administering a cancer antigen to a subject in need thereof. According to certain embodiments, the method further comprises administering an adjuvant and an anti-PD-1 antibody. In certain embodiments, the method further comprises administering radiation and/or a chemotherapeutic agent. In certain embodiments, the methods are clinically proven safe, clinically proven effective, or both.
Subjects topically apply AR100DP1 twice per day with at least 4 hour interval. The daily dosage of 1.25% AR100DP1 topical administration is 31.25 mg/day (1.25% × 1,250 × 2 = 31.25).
Participants in the foam roller+exercise group underwent foam roller application, which is a self-myofascial release method, 2 days a week for 6 weeks in addition to exercises. Medium-hard foam rollers were used in the applications. Foam roller application was performed on thoracolumbar fascia, iliotibial band, hamstring, gastro-soleus, peroneals and plantar fascia for 60 seconds on each region. A metronome was used to determine the rhythm during foam roller application. The rhythm of the metronome was set to 60 beats per minute (60 rpm). When determining the amount of load on the tissue, the participants were told to give the maximum amount of load possible.
This study was a multi-site, Phase I/II, open-label, dose-escalation study. The study included the first-in-human (FIH) dose and dose ranging groups for all four vaccines in healthy younger participants (aged 18 to 55 years \[years\]) and older participants (aged 56 to 85 years). The conducted Part A followed a dose escalation design. Discretionary dose de-escalation and refinement was also planned. Study participants with the FIH immunization and any subsequent dose escalation cohorts were immunized using a sentinel dosing/subject staggering. For any dose de-escalation or dose-refinement cohorts in younger adults, i.e., cohorts with doses lower than previously tested, participants were dosed using a subject staggering process. Cohorts in older participants were optional and dependent on acceptability of dosing in younger participants. Part A consisted of a treatment phase and a follow-up phase.

For the BNT162a1 3 µg arm, the Safety Review Committee (SRC) decided to stop dosing after 6 treated participants and to not administer the boost immunization (Dose 2). For the BNT162b1 60 µg arm, the SRC decided to not administer the boost immunization (Dose 2) for the 12 participants.
Many Veterans suffer from sleep disordered breathing with a high prevalence of undiagnosed obstructive sleep apnea. One test that can be effective in the diagnosis of sleep apnea is the polysomnogram (PSG). Split-night PSG consists of a diagnostic phase in the first half of the night and a continuous positive airway pressure titration (CPAP) in the second half of the night. CPAP is the standard, most effective therapy for obstructive sleep apnea. Due to the unfamiliar sleep environment of the laboratory and instrumentation that must be used (application of electroencephalogram leads), patients are frequently not able to sleep adequately. In these cases, the PSG must be repeated. Oral hypnotic agents are often used as a pre-medication to increase the yield of PSG in an attempt to decrease the need for repeat studies.

Numerous data is available on the effects of premedication with oral short-acting hypnotics on PSG quality and efficacy of CPAP titration. In one study, eszopiclone, a nonbenzodiazepine gaba-receptor agonist short-acting hypnotic, has been shown to improve PSG quality and CPAP titration. Another short-acting hypnotic, ramelteon, was recently approved by FDA but the effects of ramelteon in improving PSG quality and efficacy of CPAP titration are unclear. The advantage of ramelteon over eszopiclone is the lack of drug dependency or abuse potential. This study aims to evaluate the efficacy of ramelteon compared to eszopiclone when administered prior to split-night PSG and CPAP titration.
Corneal blindness is an important contributor to the burden of global blindness and has a greater prevalence in low-income countries of the developing world where resources and infrastructure are limited. The causes of corneal blindness too are different from high-income countries and include infectious keratitis, ocular trauma, and xerophthalmia. Persons with these indications tend to have unfavourable outcomes after corneal transplantation, limiting their chances of benefitting from this sight-saving procedure. However, most causes of corneal blindness in the developing world are preventable. This highlights the importance of understanding the unique challenges in these regions and the need for targeted interventions. This article discusses various prevention strategies, including primordial, primary, and secondary prevention, aimed at reducing the burden of corneal blindness in low-income countries. These include capacity building, training, and awareness campaigns to reduce the risk factors of ocular trauma, infectious keratitis, and to improve access to first aid. It is also important to promote safe eye practices and tackle nutritional deficiencies through public health interventions and policy changes. Providing the required training to general ophthalmologists in the management of basic corneal surgeries and diseases and enhancing the accessibility of eye care services in rural areas will ensure early treatment and prevent sequelae. Current treatment modalities belong to the tertiary level of prevention and are largely limited to corneal transplantation. In developing nations, there is a scarcity of donor corneal tissue necessitating an urgent expansion of eye banking services. Alternative approaches to corneal transplantation such as 3D printed corneas, cultured stem cells, and biomaterials should also be explored to meet this demand. Thus, there is a need for collaborative efforts between healthcare professionals, policymakers, and communities to implement effective prevention strategies and reduce the prevalence of corneal blindness in the developing world.
PURPOSE:A white hair preventing cosmetic having synergistically enhanced effects, containing minoxidil and levodopa as active ingredients. CONSTITUTION:A white hair preventing cosmetic containing 0.1-1wt% minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxide) and 0.1-0.25wt% levodopa[(-)-3(3,4- dihydroxyphenyl)L-alanine] as active ingredient in a cosmetic base. Minoxidil is dissolved in a solvent such as an alcohol, water, etc., levodopa is dissolved in hydrochloric acid, etc. first since it is dissolved in a dilute acid well and neutralized with a solution of caustic soda, etc. Both the solutions are blended with perfume, wetting agent, refreshing agent, skin irritating agent, etc., used for hair lotion, hair tonic, etc., to give the white hair preventing agent. A hair lotion type is most effective, having no side effect.
OBJECTIVE: The objective was to determine the prevalence and clinical correlates of nonmotor symptoms in Parkinson's disease patients in movement disorders outpatient clinics.
METHODS: We enrolled all consecutive PD patients who visited our movement disorders outpatient clinics between January and December 2023; and agreed to participate in the study. In addition to the evaluation of demographic and clinical features, clinical scales, including the MDS-UPDRS, NMSS, and FOOGQ, were performed.
RESULTS: Overall, we enrolled 163 PD subjects with a mean age of 63.9 ± 10.4 (F/M = 27/136). The disease duration was 3.5 (20) y [median (range)]. The median score of the NMSS was 41 points. The NMSs burden levels were severe in 25.2%, and very severe in 25.2% of the subjects. The subitems with the highest scores were sleep/fatigue, mood/cognition, urinary, and miscellaneous. The analyses within the patient group with newly diagnosed PD also revealed high NMSS scores. Comparisons of the NMSS between distinct PD stages revealed greater NMSS scores in the severe stage than in the mild stage (p = 0.001). Correlation analyses between the clinical scores and the NMSS scores revealed positive correlations between the NMSS scores and the scores on all the clinical scales including the MDS-UPDRS 1-4, and FOGQ.
CONCLUSION: We reported the first data regarding the NMS burden in PD patients from Turkey. We found a high prevalence and severity of various domains of NMSs, most of which were sleep/fatigue, mood/cognition, urinary, and miscellaneous. More than half of the patients had severe to very severe NMS burden. Although NMSs were more common severe-stage disease, they were also prevalent in the subgroup with newly diagnosed patients.